Organogenesis Holdings Inc. Company News: Berger Montague Investigating Allegations of Securities Fraud Against Organogenesis Holdings Inc. (ORGO); The deadline for the lead applicant is February 8, 2022 | 2022-01-24 | Press Releases
Philadelphia, Pa.–(Newsfile Corp. – Jan. 24, 2022) – Berger Montague is investigating allegations of securities fraud on behalf of investors who purchased the securities of Organogenesis Holdings Inc. (“Organogenesis” or the “Corporation “) (NASDAQ:ORGO) between From March 17, 2021 to October 11, 2021 (the “Class Period”).
If you purchased Organogenesis securities during the Class Period, wish to discuss Berger Montague’s investigation, or have any questions regarding your rights or interests, please contact attorneys Andrew Abramowitz at [email protected] or (215) 875-3015, or Michael Dell’Angelo at [email protected] or (215) 875-3080 or visit: https://bergermontague.com/cases/berger-montague-investigates-securities-fraud-against-organogenesis-holdings-inc/.
Whistleblowers: Anyone with nonpublic information regarding organogenesis is encouraged to confidentially participate in Berger Montague’s investigation or take advantage of the SEC’s whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.
Organogenesis is a regenerative medicine company that develops, manufactures and markets solutions for the advanced wound care, surgical and sports medicine markets.
According to a recently filed lawsuit, on October 12, 2021, an anonymous report published on Value Investors Clubs found that Organogenesis was wrongfully billing the federal government $250 million per year. The report further alleged that the company set an “exorbitant” price for its new bandage, Affinity, which Medicare reimbursed, while making the product lucrative for doctors through deep discounts.
Following this news, Organogenesis’ stock price fell $1.70 per share, or 14%, to close at $10.35 per share on October 12, 2021.
Shepherd Montague, with offices in Philadelphia, Minneapolis, Washington, D.C. and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for more than five decades and acts as lead counsel before the courts. across the United States.
Andrew Abramowitz, Senior Counsel
Michael Dell’Angelo, executive shareholder
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111327